
    
      This is a multi-institution, prospective, single arm Phase II trial of lenalidomide in a
      combination with dexamethasone and daratumumab (DRd lite) with no blinding or randomization.
      This study will enroll 44 patients over 36 months.

      Primary Objectives:

        1. Evaluate Response rate

        2. Evaluate Side effects

      Secondary Objectives:

        1. Evaluate Time on therapy

        2. Evaluate Progression free survival

        3. Evaluate Time to the next line of therapy

        4. Assess Quality of life
    
  